Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Clinical Epigenetics International Meeting
Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy.
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
American Neurological Association Annual 2012 Annual Meeting
The 10th European Congress of Neuropathology
Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Maternal and perinatal outcomes in pregnancies with multiple sclerosis: a case-control study.
Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio
Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature.
Patient centered decision making: Use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
CHMP determines dimethyl fumarate in TECFIDERA® to be a new active substance in the European Union
Immunology 2016
Dimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal Protection.
Use of rituximab in multiple sclerosis: current progress and future perspectives.
Daclizumab in multiple sclerosis: a high-yield extension study.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
Dimethyl Fumarate Protects Brain From Damage Produced by Intracerebral Hemorrhage by Mechanism Involving Nrf2.
FDA product review for daclizumab
Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series.
Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate.
'Clinically definite benign multiple sclerosis', an unwarranted conceptual hodgepodge: evidence from a 30-year observational study.
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).
Biomarkers of disease activity in multiple sclerosis.
How integrated are neurology and palliative care services? Results of a multicentre mapping exercise.

Pages